No Data
No Data
No Data
No Data
No Data
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024
Tonghua Dongbao Pharmaceutical (SHA:600867) booked a net profit attributable to shareholders of 214.7 million yuan in the first quarter of the year, slipping 14.3% from 250.4 million yuan a year earli
MT NewswiresApr 29 05:13 ET
Tonghua Dongbao (600867.SH) announced first-quarter results, net profit of 215 million yuan, a year-on-year decrease of 14.28%
Tonghua Dongbao (600867.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 5.9 during the reporting period...
Zhitong FinanceApr 26 06:37 ET
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Zhitong FinanceApr 24 03:48 ET
Tonghua Dongbao (600867.SH): GLP-1/GIP dual-target receptor agonist (THDBH120 for injection) has been clinically approved for weight loss indications
Gelonghui, April 24, Tonghua Dongbao (600867.SH) announced that Dongbao Zixing (Hangzhou) Biomedical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of the company, recently obtained a clinical trial approval notice from the Drug Evaluation Center (CDE) of the China Drug Administration for injectable THDBH120 weight loss indications. Injectable THDBH120 is a glucagon-like peptide-1 (GLP-1) receptor and glucose-insulin-stimulating polypeptide (GIP) receptor dual-target agonist. It integrates the two insulin-promoting effects of GLP-1 and GIP into more than one
Gelonghui FinanceApr 24 03:39 ET
Tonghua Dongbao (600867.SH): Participates in the national centralized drug procurement (insulin special continuation) to be selected
Gelonghui, April 23 | Tonghua Dongbao (600867.SH) announced that on April 23, 2024, the company participated in the national centralized drug procurement (insulin special continuation) declaration process organized by the State Organization's Centralized Drug Procurement and Use Joint Procurement Office (referred to as the “Joint Procurement Office”). Company human insulin injection, sperm protein human insulin injection, argentine human insulin mixed injection (30R), sperm protein human insulin mixed injection (40R), sperm protein human insulin mixed injection (50R), glargine insulin injection, menthong insulin injection, menthong insulin 3
Gelonghui FinanceApr 23 05:12 ET
Is Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Latest Stock Performance A Reflection Of Its Financial Health?
Tonghua Dongbao Pharmaceutical's (SHSE:600867) stock is up by a considerable 10% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is th
Simply Wall StApr 22 19:08 ET
No Data
No Data